JP2023552846A - メタニューモウイルスのｆ－タンパク質に結合する抗体およびその使用 - Google Patents

メタニューモウイルスのｆ－タンパク質に結合する抗体およびその使用 Download PDF

Info

Publication number
JP2023552846A
JP2023552846A JP2023535046A JP2023535046A JP2023552846A JP 2023552846 A JP2023552846 A JP 2023552846A JP 2023535046 A JP2023535046 A JP 2023535046A JP 2023535046 A JP2023535046 A JP 2023535046A JP 2023552846 A JP2023552846 A JP 2023552846A
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
sequence
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023535046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552846A5 (enExample
Inventor
ベニーニ，ファビオ
コルティ，ダヴィデ
デマルコ，アンナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Humabs Biomed SA
Original Assignee
Humabs Biomed SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed SA filed Critical Humabs Biomed SA
Publication of JP2023552846A publication Critical patent/JP2023552846A/ja
Publication of JP2023552846A5 publication Critical patent/JP2023552846A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
JP2023535046A 2020-12-08 2021-12-07 メタニューモウイルスのｆ－タンパク質に結合する抗体およびその使用 Pending JP2023552846A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP2020085014 2020-12-08
EPPCT/EP2020/085014 2020-12-08
EPPCT/EP2020/085747 2020-12-11
EP2020085747 2020-12-11
PCT/EP2021/084520 WO2022122704A1 (en) 2020-12-08 2021-12-07 Antibodies binding to f-protein of metapneumovirus and uses thereof

Publications (2)

Publication Number Publication Date
JP2023552846A true JP2023552846A (ja) 2023-12-19
JP2023552846A5 JP2023552846A5 (enExample) 2024-11-22

Family

ID=78844890

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023535046A Pending JP2023552846A (ja) 2020-12-08 2021-12-07 メタニューモウイルスのｆ－タンパク質に結合する抗体およびその使用

Country Status (4)

Country Link
US (1) US20240034772A1 (enExample)
EP (1) EP4259654A1 (enExample)
JP (1) JP2023552846A (enExample)
WO (1) WO2022122704A1 (enExample)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020236974A1 (en) * 2019-05-21 2020-11-26 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
JP4976376B2 (ja) * 2005-04-08 2012-07-18 メディミューン，エルエルシー 哺乳動物メタニューモウイルスに対する抗体
JP2010505876A (ja) * 2006-10-04 2010-02-25 ザ スクリプス リサーチ インスティテュート ヒトメタニューモウイルスを中和するヒト抗体
EP2158318A2 (en) 2007-05-14 2010-03-03 Biogen Idec MA, Inc. Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
PL2350128T3 (pl) 2008-10-22 2015-03-31 Inst Res Biomedicine Sposoby wytwarzania przeciwciał z komórek plazmatycznych
US8326547B2 (en) 2009-10-07 2012-12-04 Nanjingjinsirui Science & Technology Biology Corp. Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
WO2016103238A1 (en) 2014-12-24 2016-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant metapneumovirus f proteins and their use
CN110035771B (zh) * 2016-10-21 2024-03-08 阿迪马布有限责任公司 抗呼吸道合胞病毒抗体及其产生和使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020236974A1 (en) * 2019-05-21 2020-11-26 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CORTI D. ET AL., NATURE, vol. 501, JPN6025042449, 2013, pages 439 - 443, ISSN: 0005712106 *
DONDELINGER M. ET AL, FRONT IMMUNOL, vol. Vol. 9:2278, JPN6025042451, 2018, ISSN: 0005712108 *
WILLIAMS JV. ET AL., J VIROL, vol. 81, JPN6025042450, 2007, pages 8315 - 8324, ISSN: 0005712107 *

Also Published As

Publication number Publication date
US20240034772A1 (en) 2024-02-01
WO2022122704A1 (en) 2022-06-16
EP4259654A1 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
US11643465B2 (en) Anti-PD-1 antibodies
TW202204397A (zh) 對冠狀病毒s蛋白質具特異性之化合物及其用途
KR20210131336A (ko) Il-7r 알파 서브유닛에 대한 항체 및 이의 용도
KR20210109587A (ko) 인간 il-4ra에 대한 항체 및 이의 용도
JP2018511322A (ja) イヌインターロイキン４受容体アルファに対する抗体
CN116194476A (zh) 针对sars-cov-2的抗体和其使用方法
CN113544148A (zh) 中和乙型肝炎病毒的抗体和其用途
JP2020531000A (ja) ジカウイルスエピトープに特異的に結合する多重特異性抗体及びその使用
EP4353744A1 (en) Antibody against respiratory syncytial virus and use thereof
WO2020260315A1 (en) Deimmunized antibodies binding to alpha-4 integrin and uses thereof
CN114206921B (zh) 与疟原虫环子孢子蛋白结合的抗体及其用途
US20250129142A1 (en) Antibodies binding to tetanus toxin and uses thereof
CN112912398B (zh) 新颖抗体和核苷酸序列及其用途
US20260028391A1 (en) Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
JP2023552846A (ja) メタニューモウイルスのｆ－タンパク質に結合する抗体およびその使用
CN116848133A (zh) 结合偏肺病毒f蛋白的抗体及其用途
CN115304672A (zh) 冠状病毒抗体及其应用
US20220372114A1 (en) Sars-cov-2 spike protein antibodies
WO2025015321A1 (en) Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
HK40070165A (en) Antibodies binding to plasmodium circumsporozoite protein and uses thereof
OA20886A (en) Antibodies binding to plasmodium circumsporozoite protein and uses thereof.
HK40056051A (en) Antibodies that neutralize hepatitis b virus and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241114

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250519

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251215

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260303